Short-term effect of dopaminergic medication on speech in early-stage Parkinson's disease

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21230%2F22%3A00356695" target="_blank" >RIV/68407700:21230/22:00356695 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/22:10442759

Result on the web

<a href="https://doi.org/10.1038/s41531-022-00286-y" target="_blank" >https://doi.org/10.1038/s41531-022-00286-y</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41531-022-00286-y" target="_blank" >10.1038/s41531-022-00286-y</a>

Result language

angličtina

Original language name

Short-term effect of dopaminergic medication on speech in early-stage Parkinson's disease

Original language description

The effect of dopaminergic medication on speech has rarely been examined in early-stage Parkinson's disease (PD) and the respective literature is inconclusive and limited by inappropriate design with lack of PD control group. The study aims to examine the short-term effect of dopaminergic medication on speech in PD using patients with good motor responsiveness to levodopa challenge compared to a control group of PD patients with poor motor responsiveness. A total of 60 early-stage PD patients were investigated before (OFF) and after (ON) acute levodopa challenge and compared to 30 age-matched healthy controls. PD patients were categorised into two clinical subgroups (PD responders vs. PD nonresponders) according to the comparison of their motor performance based on movement disorder society-unified Parkinson's disease rating scale, part Ill. Seven distinctive parameters of hypokinetic dysarthria were examined using quantitative acoustic analysis. We observed increased monopitch (p> 0.01), aggravated monoloudness (p> 0.05) and longer duration of stop consonants (p> 0.05) in PD compared to healthy controls, confirming the presence of hypokinetic dysarthria in early PD. No speech alterations from OFF to ON state were revealed in any of the two PD groups and speech dimensions investigated including monopitch, monoloudness, imprecise consonants, harsh voice, slow sequential motion rates, articulation rate, or inappropriate silences, although a subgroup of PD responders manifested obvious improvement in motor function after levodopa intake (p> 0.001). Since the short-term usage of levodopa does not easily affect voice and speech performance in PD, speech assessment may provide a medication state-independent motor biomarker of PD.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30210 - Clinical neurology

Project

<a href="/en/project/NV19-04-00120" target="_blank" >NV19-04-00120: Objective investigation of distinct speech phenotypes in newly diagnosed Parkinson's disease including effects of pharmacotherapy</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

npj Parkinsons Disease

ISSN

2373-8057

e-ISSN

—

Volume of the periodical

8

Issue of the periodical within the volume

1

Country of publishing house

GB - UNITED KINGDOM

Number of pages

6

Pages from-to

—

UT code for WoS article

000765758900001

EID of the result in the Scopus database

2-s2.0-85126192350